Recent IMRX News
- IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models • GlobeNewswire Inc. • 04/09/2024 04:00:00 PM
- Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/03/2024 08:05:00 PM
- Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors • GlobeNewswire Inc. • 03/14/2024 11:00:00 AM
- Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 • GlobeNewswire Inc. • 03/05/2024 10:00:00 PM
- Immuneering to Participate in the Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/01/2024 01:05:34 PM
- Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 12:58:59 PM
- Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:26:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:21:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:17:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:12:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:07:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:15:43 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/16/2024 09:37:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:26:06 PM
- Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/20/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:12:06 PM
- Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM